Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
February 07, 2023 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at Upcoming Investor Conferences
November 22, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 10, 2022 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
November 04, 2022 10:00 ET
|
Chinook Therapeutics, Inc.
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is...
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
November 03, 2022 10:00 ET
|
Chinook Therapeutics, Inc.
Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12...
Chinook Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
October 14, 2022 08:00 ET
|
Chinook Therapeutics, Inc.
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the...
Chinook Therapeutics to Present at Upcoming Investor Conferences
September 01, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...